Anoro Ellipta side effects Anoro Ellipta can cause mild or serious side effects. The following lists contain some of the key side effects that may occur while taking Anoro Ellipta. These lists do not ...
The U.S. Food and Drug Administration today approved Anoro Ellipta (umeclidinium and vilanterol inhalation powder) for the once-daily, long-term maintenance treatment of airflow obstruction in ...
Avoid co-administration of Anoro with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects such as cardiovascular effects, worsening of ...
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ Ellipta ...
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
MISSISSAUGA, ON, Jan. 9, 2014 /CNW/ - GlaxoSmithKline Inc. and Theravance Inc. today announced that ANORO™ ELLIPTA™ was approved in Canada on December 23, 2013, for the long-term once-daily ...
Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.
Anoro Ellipta combines umeclidinium 62.5mcg, a long-acting muscarinic antagonist, and vilanterol 25mcg, a long-acting beta2-agonist (LABA). Umeclidinium exerts its effect through inhibition of M3 ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ANORO ELLIPTA contains the active ingredients umeclidinium bromide and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results